Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The Pharm A project is a French national collaborative project aiming to determine the population pharmacokinetics of ceftazidime, ciprofloxacin, and voriconazole in paediatric patients aged one month to five years.
The licensing process was introduced in order to ensure that medicines are safe, effective and of high quality. However, over 50% of children admitted to hospital in France and Europe will receive an unlicensed or off-label medicine. This occurs for most drugs in children less than 6 years of age. They represent a particularly vulnerable subgroup of the paediatric population.
There are major practical and ethical issues in relation to studying medicines in paediatric patients aged 5 years or less.
After parental informed consent, sampling strategy will be randomized depending on the drug and the age group (2 samples in patients below 2 years and 3 samples in patients from 2 to 5 years).
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients treated with Ceftazidime | Experimental |
| |
| Patients treated with Ciprofloxacin | Experimental |
| |
| Patients treated with Voriconazole | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Ceftazidime | Drug | Bloods sampling on patient treated with Ceftazidime between 48 hours and 4 days after beginning of treatment. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Population pharmacokinetic parameters and factors explaining variability | Population Pharmacokinetic Parameters and variability factors (Sex, Age, Genetic factors...) for ceftazidime, ciprofloxacin and voriconazole. According to the age of participants, 2 or 3 bloods sampling will be take between 2 and 4 days after the beginning of the treatment. | Between 2 and 4 days after the begining of the treatment |
| Measure | Description | Time Frame |
|---|---|---|
| Covariability factors explaining the variability (age, biological data, pharmacokinetics factors, associated treatments...) | Between 2 and 4 days after the beginning of the treatment |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not Applicable
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Stéphanie Bui, Dr | University Hospital Bordeaux, France | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHU de Bordeaux, Hôpital Pellegrin | Bordeaux | 33076 | France | |||
| Hospices Civils de Lyon |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 32457995 | Derived | Bui S, Facchin A, Ha P, Bouchet S, Leroux S, Nacka F, Fayon M, Jacqz-Aigrain E. Population pharmacokinetics of ceftazidime in critically ill children: impact of cystic fibrosis. J Antimicrob Chemother. 2020 Aug 1;75(8):2232-2239. doi: 10.1093/jac/dkaa170. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D002442 | Ceftazidime |
| D002939 | Ciprofloxacin |
| D065819 | Voriconazole |
| ID | Term |
|---|---|
| D002509 | Cephaloridine |
| D002511 | Cephalosporins |
| D047090 | beta-Lactams |
| D007769 | Lactams |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Ciprofloxacin | Drug | Bloods sampling on patient treated with Ciprofloxacin between 48 hours and 4 days after beginning of treatment. |
|
| Voriconazole | Drug | Bloods sampling on patient treated with Voriconazole between 48 hours and 4 days after beginning of treatment. |
|
| Bron |
| 69500 |
| France |
| CHU Clermont Ferrand | Clermont-Ferrand | 63000 | France |
| CHU de Dijon | Dijon | 21079 | France |
| CHU de Grenoble | Grenoble | 38043 | France |
| CHRU Lille | Lille | 59037 | France |
| AP-HM, Hôpital La Timone | Marseille | 13005 | France |
| CHU Montpellier | Montpellier | 34925 | France |
| APHP - Hôpital NEcker | Paris | 75015 | France |
| AP-HP - Hôpital Robert Debré | Paris | 75019 | France |
| CHU Poitiers | Poitiers | 86000 | France |
| CHU Rouen | Rouen | 76031 | France |
| CHU Toulouse | Toulouse | 31059 | France |
| CHU tours | Tours | 37044 | France |
| D000577 |
| Amides |
| D009930 | Organic Chemicals |
| D013843 | Thiazines |
| D013457 | Sulfur Compounds |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |
| D024841 | Fluoroquinolones |
| D042462 | 4-Quinolones |
| D015363 | Quinolones |
| D011804 | Quinolines |
| D014230 | Triazoles |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |